Calreticulin, a therapeutic target?

References

• Michalak M, Groenendyk J, Szabo E, et al. Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum. Biochem J. 2009 Feb 1;417(3):651–666.
   PubMed Web of Science ®Google Scholar
• Michalak M, Corbett EF, Mesaeli N, et al. Calreticulin: one protein, one gene, many functions. Biochem J. 1999 Dec 1;344(Pt 2):281–292.
   PubMed Web of Science ®Google Scholar
• Ostwald TJ, MacLennan DH, Dorrington KJ. Effects of cation binding on the conformation of calsequestrin and the high affinity calcium-binding protein of sarcoplasmic reticulum. J Biol Chem. 1974 Sep 25;249(18):5867–5871.
   PubMed Web of Science ®Google Scholar
• Cooper GM, Hausman BE. The cell: a molecular approach. 6th ed. Sunderland (MA): Sinauer; 2013.
   Google Scholar
• Eggleton P, Michalak M. Calreticulin. 2nd ed. Georgetown, TX: Landes Bioscience/Eurekah.com; 2003.
   Google Scholar
• Gold LI, Eggleton P, Sweetwyne MT, et al. Calreticulin: non-endoplasmic reticulum functions in physiology and disease. FASEB J. 2010 Mar;24(3):665–683.
   PubMed Web of Science ®Google Scholar
• Goicoechea S, Orr AW, Pallero MA, et al. Thrombospondin mediates focal adhesion disassembly through interactions with cell surface calreticulin. J Biol Chem. 2000 Nov 17;275(46):36358–36368.
   PubMed Web of Science ®Google Scholar
• Gardai SJ, McPhillips KA, Frasch SC, et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell. 2005 Oct 21;123(2):321–334.
   PubMed Web of Science ®Google Scholar
• Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13(1):54–61.
   PubMed Web of Science ®Google Scholar
• Obeid M, Tesniere A, Panaretakis T, et al. Ecto-calreticulin in immunogenic chemotherapy. Immunol Rev. 2007;220:22–34.
   PubMed Web of Science ®Google Scholar
• Pike SE, Yao L, Jones KD, et al. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med. 1998 Dec 21;188(12):2349–2356.
   PubMed Web of Science ®Google Scholar
• Dai E, Stewart M, Ritchie B, et al. Calreticulin, a potential vascular regulatory protein, reduces intimal hyperplasia after arterial injury. Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):2359–2368.
   PubMed Web of Science ®Google Scholar
• Dudek-Peric AM, Ferreira GB, Muchowicz A, et al. Antitumor immunity triggered by melphalan is potentiated by melanoma cell surface-associated calreticulin. Cancer Res. 2015 Apr 15;75(8):1603–1614.
   PubMed Web of Science ®Google Scholar
• Kepp O, Gdoura A, Martins I, et al. Lysyl tRNA synthetase is required for the translocation of calreticulin to the cell surface in immunogenic death. Cell Cycle. 2010 Aug 1;9(15):3072–3077.
   PubMed Web of Science ®Google Scholar
• Ling S, Pi X, Holoshitz J. The rheumatoid arthritis shared epitope triggers innate immune signaling via cell surface calreticulin. J Immunology. 2007 Nov 1;179(9):6359–6367.
   PubMed Web of Science ®Google Scholar
• Wiersma VR, Michalak M, Abdullah TM, et al. Mechanisms of translocation of ER chaperones to the cell surface and immunomodulatory roles in cancer and autoimmunity. Front Oncol. 2015;5:7.
   PubMed Web of Science ®Google Scholar
• Martins I, Kepp O, Galluzzi L, et al. Surface-exposed calreticulin in the interaction between dying cells and phagocytes. Ann N Y Acad Sci. 2010;1209:77–82.
   PubMed Web of Science ®Google Scholar
• Martins I, Kepp O, Schlemmer F, et al. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene. 2011 Mar 10;30(10):1147–1158.
   PubMed Web of Science ®Google Scholar
• Greives MR, Samra F, Pavlides SC, et al. Exogenous calreticulin improves diabetic wound healing. Wound Repair Regen. 2012 Sep-Oct;20(5):715–730.
   PubMed Web of Science ®Google Scholar
• Nanney LB, Woodrell CD, Greives MR, et al. Calreticulin enhances porcine wound repair by diverse biological effects. Am J Pathol. 2008;173(3):610–630.
   PubMed Web of Science ®Google Scholar
• Donnelly S, Roake W, Brown S, et al. Impaired recognition of apoptotic neutrophils by the C1q/calreticulin and CD91 pathway in systemic lupus erythematosus. Arthritis Rheum. 2006 May;54(5):1543–1556.
   PubMed Web of Science ®Google Scholar
• Kasper G, Brown A, Eberl M, et al. A calreticulin-like molecule from the human hookworm Necator americanus interacts with C1q and the cytoplasmic signalling domains of some integrins. Parasite Immunol. 2001 Mar;23(3):141–152.
   PubMed Web of Science ®Google Scholar
• Kim TK, Ibelli AM, Mulenga A. Amblyomma americanum tick calreticulin binds C1q but does not inhibit activation of the classical complement cascade. Ticks Tick Borne Dis. 2015 Feb;6(1):91–101.
   PubMed Web of Science ®Google Scholar
• Kishore U, Sontheimer RD, Sastry KN, et al. Release of calreticulin from neutrophils may alter C1q-mediated immune functions. Biochem J. 1997 Mar 1;322(Pt 2):543–550.
   PubMed Web of Science ®Google Scholar
• Kovacs H, Campbell ID, Strong P, et al. Evidence that C1q binds specifically to CH2-like immunoglobulin gamma motifs present in the autoantigen calreticulin and interferes with complement activation. Biochemistry. 1998 Dec 22;37(51):17865–17874.
   PubMed Web of Science ®Google Scholar
• Ogden CA, deCathelineau A, Hoffmann PR, et al. C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells. J Exp Med. 2001 Sep 17;194(6):781–795.
   PubMed Web of Science ®Google Scholar
• Verneret M, Tacnet-Delorme P, Osman R, et al. Relative contribution of c1q and apoptotic cell-surface calreticulin to macrophage phagocytosis. J Innate Immun. 2014;6(4):426–434.
   PubMed Web of Science ®Google Scholar
• Gilardini Montani MS, D’Eliseo D, Cirone M, et al. Capsaicin-mediated apoptosis of human bladder cancer cells activates dendritic cells via CD91. Nutrition. 2015 Apr;31(4):578–581.
   PubMed Web of Science ®Google Scholar
• Tarr J, Eggleton P. Immune function of C1q and its modulators CD91 and CD93. Crit Rev Immunol. 2005;25(4):305–330.
   PubMed Web of Science ®Google Scholar
• Zhou YJ, Messmer MN, Binder RJ. Establishment of tumor-associated immunity requires interaction of heat shock proteins with CD91. Cancer Immunol Res. 2014 Mar;2(3):217–228.
   PubMed Web of Science ®Google Scholar
• Chao MP, Jaiswal S, Weissman-Tsukamoto R, et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med. 2010 Dec 22;2(63):63ra94.
   PubMed Web of Science ®Google Scholar
• Paidassi H, Tacnet-Delorme P, Verneret M, et al. Investigations on the C1q-calreticulin-phosphatidylserine interactions yield new insights into apoptotic cell recognition. J Mol Biol. 2011 Apr 29;408(2):277–290.
   PubMed Web of Science ®Google Scholar
• de Bruyn M, Wiersma VR, Helfrich W, et al. The ever-expanding immunomodulatory role of calreticulin in cancer immunity. Front Oncol. 2015;5:35.
   PubMed Web of Science ®Google Scholar
• Duus K, Pagh RT, Holmskov U, et al. Interaction of calreticulin with CD40 ligand, TRAIL and fas ligand. Scand J Immunol. 2007 Nov;66(5):501–507.
   PubMed Web of Science ®Google Scholar
• Tarr JM, Winyard PG, Ryan B, et al. Extracellular calreticulin is present in the joints of patients with rheumatoid arthritis and inhibits FasL (CD95L)-mediated apoptosis of T cells. Arthritis Rheum. 2010 Oct;62(10):2919–2929.
   PubMed Web of Science ®Google Scholar
• Chen B, Wu Z, Xu J, et al. Calreticulin binds to fas ligand and inhibits neuronal cell apoptosis induced by ischemia-reperfusion injury. Biomed Res Int. 2015;2015:895284.
   PubMedGoogle Scholar
• Chen D, Texada DE, Duggan C, et al. Surface calreticulin mediates muramyl dipeptide-induced apoptosis in RK13 cells. J Biol Chem. 2005 Jun 10;280(23):22425–22436.
   PubMed Web of Science ®Google Scholar
• Kaczmarek A, Vandenabeele P, Krysko DV. Necroptosis: the release of damage-associated molecular patterns and its physiological relevance. Immunity. 2013 Feb 21;38(2):209–223.
   PubMed Web of Science ®Google Scholar
• Sadasivan B, Lehner PJ, Ortmann B, et al. Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP. Immunity. 1996 Aug;5(2):103–114.
   PubMed Web of Science ®Google Scholar
• Farmery MR, Allen S, Allen AJ, et al. The role of ERp57 in disulfide bond formation during the assembly of major histocompatibility complex class I in a synchronized semipermeabilized cell translation system. J Biol Chem. 2000 May 19;275(20):14933–14938.
   PubMed Web of Science ®Google Scholar
• Peaper DR, Cresswell P. Regulation of MHC class I assembly and peptide binding. Annu Rev Cell Dev Biol. 2008;24:343–368.
   PubMed Web of Science ®Google Scholar
• Gao B, Adhikari R, Howarth M, et al. Assembly and antigen-presenting function of MHC class I molecules in cells lacking the ER chaperone calreticulin. Immunity. 2002 Jan;16(1):99–109.
   PubMed Web of Science ®Google Scholar
• Li SS, Ivanoff A, Bergstrom SE, et al. T lymphocyte expression of thrombospondin-1 and adhesion to extracellular matrix components. Eur J Immunol. 2002 Apr;32(4):1069–1079.
   PubMed Web of Science ®Google Scholar
• Li SS, Forslow A, Sundqvist KG. Autocrine regulation of T cell motility by calreticulin-thrombospondin-1 interaction. J Immunology. 2005 Jan 15;174(2):654–661.
   PubMed Web of Science ®Google Scholar
• Dupuis M, Schaerer E, Krause KH, et al. The calcium-binding protein calreticulin is a major constituent of lytic granules in cytolytic T lymphocytes. J Exp Med. 1993 Jan 1;177(1):1–7.
   PubMed Web of Science ®Google Scholar
• Fraser SA, Karimi R, Michalak M, et al. Perforin lytic activity is controlled by calreticulin. J Immunology. 2000 Apr 15;164(8):4150–4155.
   PubMed Web of Science ®Google Scholar
• Sipione S, Ewen C, Shostak I, et al. Impaired cytolytic activity in calreticulin-deficient CTLs. J Immunol. 2005 Mar 15;174(6):3212–3219.
   PubMed Web of Science ®Google Scholar
• Hodge JW, Garnett CT, Farsaci B, et al. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J Cancer Journal International Du Cancer. 2013 Aug 1;133(3):624–636.
   PubMed Web of Science ®Google Scholar
• Gameiro SR, Jammeh ML, Wattenberg MM, et al. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget. 2014 Jan 30;5(2):403–416.
   PubMed Web of Science ®Google Scholar
• Hodge JW, Kwilas A, Ardiani A, et al. Attacking malignant cells that survive therapy: exploiting immunogenic modulation. Oncoimmunology. 2013 Dec 1;2(12):e26937.
   PubMedGoogle Scholar
• Gameiro SR, Ardiani A, Kwilas A, et al. Radiation-induced survival responses promote immunogenic modulation to enhance immunotherapy in combinatorial regimens. Oncoimmunology. 2014;3:e28643.
   Google Scholar
• Sheng W, Chen C, Dong M, et al. Overexpression of calreticulin contributes to the development and progression of pancreatic cancer. J Cell Physiol. 2014 Jul;229(7):887–897.
   PubMed Web of Science ®Google Scholar
• Yang MS, Wang HS, Wang BS, et al. A comparative proteomic study identified calreticulin and prohibitin up-regulated in adrenocortical carcinomas. Diagn Pathol. 2013;8:58.
   PubMed Web of Science ®Google Scholar
• Kabbage M, Trimeche M, Bergaoui S, et al. Calreticulin expression in infiltrating ductal breast carcinomas: relationships with disease progression and humoral immune responses. Tumour Biol. 2013 Apr;34(2):1177–1188.
   PubMed Web of Science ®Google Scholar
• Lwin ZM, Guo C, Salim A, et al. Clinicopathological significance of calreticulin in breast invasive ductal carcinoma. Mod Pathol. 2010 Dec;23(12):1559–1566.
   PubMed Web of Science ®Google Scholar
• Chen CN, Chang CC, Su TE, et al. Identification of calreticulin as a prognosis marker and angiogenic regulator in human gastric cancer. Ann Surg Oncol. 2009 Feb;16(2):524–533.
   PubMed Web of Science ®Google Scholar
• Du XL, Hu H, Lin DC, et al. Proteomic profiling of proteins dysregulted in Chinese esophageal squamous cell carcinoma. J Mol Med. 2007 Aug;85(8):863–875.
   PubMed Web of Science ®Google Scholar
• Alaiya A, Roblick U, Egevad L, et al. Polypeptide expression in prostate hyperplasia and prostate adenocarcinoma. Anal Cell Pathol. 2000;21(1):1–9.
   PubMed Web of Science ®Google Scholar
• Gao H, Yu B, Yan Y, et al. Correlation of expression levels of ANXA2, PGAM1, and CALR with glioma grade and prognosis. J Neurosurg. 2013 Apr;118(4):846–853.
   PubMed Web of Science ®Google Scholar
• St-Arnaud R, Prud’homme J, Leung-Hagesteijn C, et al. Constitutive expression of calreticulin in osteoblasts inhibits mineralization. J Cell Biol. 1995 Dec;131(5):1351–1359.
   PubMed Web of Science ®Google Scholar
• Coppolino MG, Dedhar S. Calreticulin. Int J Biochem Cell Biol. 1998 May;30(5):553–558.
   PubMed Web of Science ®Google Scholar
• Basu S, Srivastava PK. Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor- and peptide-specific immunity. J Exp Med. 1999 Mar 1;189(5):797–802.
   PubMed Web of Science ®Google Scholar
• Pike SE, Yao L, Setsuda J, et al. Calreticulin and calreticulin fragments are endothelial cell inhibitors that suppress tumor growth. Blood. 1999;94(7):2461–2468.
   PubMed Web of Science ®Google Scholar
• Cheng WF, Hung CF, Chai CY, et al. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest. 2001;108(5):669–678.
   PubMed Web of Science ®Google Scholar
• Xiao F, Wei Y, Yang L, et al. A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin. Gene Ther. 2002 Sep;9(18):1207–1213.
   PubMed Web of Science ®Google Scholar
• Yao L, Pike SE, Pittaluga S, et al. Anti-tumor activities of the angiogenesis inhibitors interferon-inducible protein-10 and the calreticulin fragment vasostatin. Cancer Immunol Immunother. 2002 Sep;51(7):358–366.
   PubMed Web of Science ®Google Scholar
• Vucenik I, Passaniti A, Vitolo MI, et al. Anti-angiogenic activity of inositol hexaphosphate (IP6). Carcinogenesis. 2004 Nov;25(11):2115–2123.
   PubMed Web of Science ®Google Scholar
• Krysko DV, Garg AD, Kaczmarek A, et al. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012 Dec;12(12):860–875.
   PubMed Web of Science ®Google Scholar
• Garg AD, Galluzzi L, Apetoh L, et al. Molecular and translational classifications of DAMPs in immunogenic cell death. Front Immunol. 2015;6:588.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vacchelli E, Bravo-San Pedro JM, et al. Classification of current anticancer immunotherapies. Oncotarget. 2014 Dec 30;5(24):12472–12508.
   PubMed Web of Science ®Google Scholar
• Kepp O, Senovilla L, Vitale I, et al. Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology. 2014 Oct;3(9):e955691.
   PubMed Web of Science ®Google Scholar
• Liu R, Gong J, Chen J, et al. Calreticulin as a potential diagnostic biomarker for lung cancer. Cancer Immunol Immunother. 2012 Jun;61(6):855–864.
   PubMed Web of Science ®Google Scholar
• Hsu WM, Hsieh FJ, Jeng YM, et al. Calreticulin expression in neuroblastoma--a novel independent prognostic factor. Ann Oncol. 2005 Feb;16(2):314–321.
   PubMed Web of Science ®Google Scholar
• Fucikova J, Becht E, Iribarren K, et al. Calreticulin expression in human non-small cell lung cancers correlates with increased accumulation of antitumor immune cells and favorable prognosis. Cancer Res. 2016 Feb 3. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Fucikova J, Moserova I, Urbanova L, et al. Prognostic and predictive value of DAMPs and DAMP-associated processes in cancer. Front Immunol. 2015;6:402.
   PubMed Web of Science ®Google Scholar
• Kang JS, Dervan PB. A sequence-specific DNA binding small molecule triggers the release of immunogenic signals and phagocytosis in a model of B-cell lymphoma. Q Rev Biophys. 2015 Nov;48(4):453–464.
   PubMed Web of Science ®Google Scholar
• Wemeau M, Kepp O, Tesniere A, et al. Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia. Cell Death Dis. 2010;1:e104.
   PubMed Web of Science ®Google Scholar
• Tufi R, Panaretakis T, Bianchi K, et al. Reduction of endoplasmic reticulum Ca2+ levels favors plasma membrane surface exposure of calreticulin. Cell Death Differ. 2008 Feb;15(2):274–282.
   PubMed Web of Science ®Google Scholar
• Nakamura K, Zuppini A, Arnaudeau S, et al. Functional specialization of calreticulin domains. J Cell Biol. 2001;154:961–972.
   PubMed Web of Science ®Google Scholar
• Baksh S, Michalak M. Expression of calreticulin in Escherichia coli and identification of its Ca2+ binding domains. J Biol Chem. 1991;266:21458–21465.
   PubMed Web of Science ®Google Scholar
• Yao L, Pike SE, Tosato G. Laminin binding to the calreticulin fragment vasostatin regulates endothelial cell function. J Leukoc Biol. 2002;71:47–53.
   PubMed Web of Science ®Google Scholar
• Hong C, Qiu X, Li Y, et al. Functional analysis of recombinant calreticulin fragment 39-272: implications for immunobiological activities of calreticulin in health and disease. J Immunol. 2010 Oct 15;185(8):4561–4569.
   PubMed Web of Science ®Google Scholar
• Fredly H, Ersvaer E, Gjertsen BT, et al. Immunogenic apoptosis in human acute myeloid leukemia (AML): primary human AML cells expose calreticulin and release heat shock protein (HSP) 70 and HSP90 during apoptosis. Oncol Rep. 2011 Jun;25(6):1549–1556.
   PubMed Web of Science ®Google Scholar
• Nuccitelli R, Berridge JC, Mallon Z, et al. Nanoelectroablation of murine tumors triggers a CD8-dependent inhibition of secondary tumor growth. Plos One. 2015;10(7):e0134364.
   PubMed Web of Science ®Google Scholar
• Garg AD, Elsen S, Krysko DV, et al. Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal. Oncotarget. 2015 Sep 29;6(29):26841–26860.
   Web of Science ®Google Scholar
• Peng RQ, Chen YB, Ding Y, et al. Expression of calreticulin is associated with infiltration of T-cells in stage IIIB colon cancer. World J Gastroenterol. 2010 May 21;16(19):2428–2434.
   PubMed Web of Science ®Google Scholar
• Vaksman O, Davidson B, Trope C, et al. Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases. Hum Pathol. 2013 Dec;44(12):2677–2683.
   PubMed Web of Science ®Google Scholar
• Chaput N, De Botton S, Obeid M, et al. Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference. J Mol Med. 2007 Oct;85(10):1069–1076.
   PubMed Web of Science ®Google Scholar
• Garg AD, Krysko DV, Verfaillie T, et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J. 2012 Mar 7;31(5):1062–1079.
   PubMed Web of Science ®Google Scholar
• Molinari R, D’Eliseo D, Manzi L, et al. The n3-polyunsaturated fatty acid docosahexaenoic acid induces immunogenic cell death in human cancer cell lines via pre-apoptotic calreticulin exposure. Cancer Immunol Immunother. 2011 Oct;60(10):1503–1507.
   PubMed Web of Science ®Google Scholar
• Panaretakis T, Joza N, Modjtahedi N, et al. The co-translocation of ERp57 and calreticulin determines the immunogenicity of cell death. Cell Death Differ. 2008 Sep;15(9):1499–1509.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Kepp O, Senovilla L, et al. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res. 2010 Jun 15;16(12):3100–3104.
   PubMed Web of Science ®Google Scholar
• White TK, Zhu Q, Tanzer ML. Cell surface calreticulin is a putative mannoside lectin which triggers mouse melanoma cell spreading. J Biol Chem. 1995 Jul 7;270(27):15926–15929.
   PubMed Web of Science ®Google Scholar
• Arosa FA, de Jesus O, Porto G, et al. Calreticulin is expressed on the cell surface of activated human peripheral blood T lymphocytes in association with major histocompatibility complex class I molecules. J Biol Chem. 1999 Jun 11;274(24):16917–16922.
   PubMed Web of Science ®Google Scholar
• Xiao G, Chung TF, Pyun HY, et al. KDEL proteins are found on the surface of NG108-15 cells. Brain Res Mol Brain Res. 1999 Oct 1;72(2):121–128.
   PubMedGoogle Scholar
• Seddiki N, Nato F, Lafaye P, et al. Calreticulin, a potential cell surface receptor involved in cell penetration of anti-DNA antibodies. J Immunol. 2001 May 15;166(10):6423–6429.
   PubMed Web of Science ®Google Scholar
• Cho JH, Homma KJ, Kanegasaki S, et al. Activation of human monocyte cell line U937 via cell surface calreticulin. Cell Stress Chaperones. 2001 Apr;6(2):148–152.
   PubMed Web of Science ®Google Scholar
• Tutuncu L, Stein P, Ord TS, et al. Calreticulin on the mouse egg surface mediates transmembrane signaling linked to cell cycle resumption. Dev Biol. 2004 Jun 1;270(1):246–260.
   PubMed Web of Science ®Google Scholar
• Elton CM, Smethurst PA, Eggleton P, et al. Physical and functional interaction between cell-surface calreticulin and the collagen receptors integrin alpha2beta1 and glycoprotein VI in human platelets. Thromb Haemost. 2002 Oct;88(4):648–654.
   PubMed Web of Science ®Google Scholar
• Vance BA, Harley PH, Backlund PS, et al. Human CD69 associates with an N-terminal fragment of calreticulin at the cell surface. Arch Biochem Biophys. 2005 Jun 1;438(1):11–20.
   PubMed Web of Science ®Google Scholar
• Zeng G, Aldridge ME, Tian X, et al. Dendritic cell surface calreticulin is a receptor for NY-ESO-1: direct interactions between tumor-associated antigen and the innate immune system. J Immunology. 2006 Sep 15;177(6):3582–3589.
   PubMed Web of Science ®Google Scholar
• Tarr JM, Young PJ, Morse R, et al. A mechanism of release of calreticulin from cells during apoptosis. J Mol Biol. 2010 Sep 3;401(5):799–812.
   PubMed Web of Science ®Google Scholar
• Lopez Sambrooks C, Carpio MA, Hallak ME. Arginylated calreticulin at plasma membrane increases susceptibility of cells to apoptosis. J Biol Chem. 2012 Jun 22;287(26):22043–22054.
   PubMed Web of Science ®Google Scholar
• Jeffery E, Peters LR, Raghavan M. The polypeptide binding conformation of calreticulin facilitates its cell-surface expression under conditions of endoplasmic reticulum stress. J Biol Chem. 2011 Jan 28;286(4):2402–2415.
   PubMed Web of Science ®Google Scholar
• Fayadat L, Siffroi-Fernandez S, Lanet J, et al. Calnexin and calreticulin binding to human thyroperoxidase is required for its first folding step(s) but is not sufficient to promote efficient cell surface expression. Endocrinology. 2000 Mar;141(3):959–966.
   PubMed Web of Science ®Google Scholar
• Cho JH, Homma K, Kanegasaki S, et al. Activation of human neutrophils by a synthetic anti-microbial peptide, KLKLLLLLKLK-NH2, via cell surface calreticulin. Eur J Biochem. 1999 Dec;266(3):878–885.
   PubMedGoogle Scholar
• Aguilar-Guzman L, Lobos-Gonzalez L, Rosas C, et al. Human survivin and Trypanosoma cruzi calreticulin act in synergy against a murine melanoma in vivo. Plos One. 2014;9(4):e95457.
   Google Scholar
• Clarke C, Smyth MJ. Calreticulin exposure increases cancer immunogenicity. Nat Biotechnol. 2007 Feb;25(2):192–193.
   PubMed Web of Science ®Google Scholar
• Fonseca-Coronado S, Ruiz-Tovar K, Perez-Tapia M, et al. Taenia solium: immune response against oral or systemic immunization with purified recombinant calreticulin in mice. Exp Parasitol. 2011 Jan;127(1):313–317.
   PubMed Web of Science ®Google Scholar
• He M-C, Wang J, Wu J, et al. Immunological activity difference between native calreticulin monomers and oligomers. Plos One. 2014;9(8):e105502.
   Google Scholar
• Hong C, Zhang T, Gao XM. Recombinant murine calreticulin fragment 39-272 expands CD1d(hi)CD5+ IL-10-secreting B cells that modulate experimental autoimmune encephalomyelitis in C57BL/6 mice. Mol Immunol. 2013 Oct;55(3–4):237–246.
   PubMed Web of Science ®Google Scholar
• Ignacio Arias J, Sepulveda C, Bravo P, et al. Comparative effect of human and Trypanosoma cruzi calreticulin in wound healing. J Tissue Eng Regen Med. 2015 Jan;9(1):41–54.
   PubMed Web of Science ®Google Scholar
• Tang XL, Liang XD, Xu RH, et al. [Preparation of rabbit anti-recombinant human calreticulin antibody and its characterization]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi = Chin J Cell Mol Immunol. 2011 Jun;27(6):641–643.
   PubMedGoogle Scholar
• Reed RC, Berwin B, Baker JP, et al. GRP94/gp96 elicits ERK activation in murine macrophages. A role for endotoxin contamination in NF-kappa B activation and nitric oxide production. J Biol Chem. 2003 Aug 22;278(34):31853–31860.
   PubMed Web of Science ®Google Scholar
• Bak SP, Amiel E, Walters JJ, et al. Calreticulin requires an ancillary adjuvant for the induction of efficient cytotoxic T cell responses. Mol Immunol. 2008 Mar;45(5):1414–1423.
   PubMed Web of Science ®Google Scholar
• Wijeyesakere SJ, Gafni AA, Raghavan M. Calreticulin is a thermostable protein with distinct structural responses to different divalent cation environments. J Biol Chem. 2011 Mar 18;286(11):8771–8785.
   PubMed Web of Science ®Google Scholar
• Huang SH, Zhao LX, Hong C, et al. Self-oligomerization is essential for enhanced immunological activities of soluble recombinant calreticulin. Plos One. 2013;8(6):e64951.
   Google Scholar
• Bajor A, Tischer S, Figueiredo C, et al. Modulatory role of calreticulin as chaperokine for dendritic cell-based immunotherapy. Clin Exp Immunol. 2011 Aug;165(2):220–234.
   PubMed Web of Science ®Google Scholar
• Waser M, Mesaeli N, Spencer C, et al. Regulation of calreticulin gene expression by calcium. J Cell Biol. 1997 Aug 11;138(3):547–557.
   PubMed Web of Science ®Google Scholar
• Xu FF, Liu XH. Calreticulin translocation aggravates endoplasmic reticulum stress-associated apoptosis during cardiomyocyte hypoxia/reoxygenation. Chin Med J (Engl). 2015 Feb 5;128(3):353–360.
   PubMed Web of Science ®Google Scholar
• Brown SB, Brown EA, Walker I. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol. 2004 Aug;5(8):497–508.
   PubMed Web of Science ®Google Scholar
• Korbelik M, Zhang W, Merchant S. Involvement of damage-associated molecular patterns in tumor response to photodynamic therapy: surface expression of calreticulin and high-mobility group box-1 release. Cancer Immunol Immunother. 2011 Oct;60(10):1431–1437.
   PubMed Web of Science ®Google Scholar
• Garg AD, Krysko DV, Vandenabeele P, et al. Hypericin-based photodynamic therapy induces surface exposure of damage-associated molecular patterns like HSP70 and calreticulin. Cancer Immunol Immunother. 2012 Feb;61(2):215–221.
   PubMed Web of Science ®Google Scholar
• Korbelik M, Banath J, Saw KM, et al. Calreticulin as cancer treatment adjuvant: combination with photodynamic therapy and photodynamic therapy-generated vaccines. Front Oncol. 2015;5:15.
   PubMed Web of Science ®Google Scholar
• Musahl AS, Huang X, Rusakiewicz S, et al. A long non-coding RNA links calreticulin-mediated immunogenic cell removal to RB1 transcription. Oncogene. 2015 Sep 24;34(39):5046–5054.
   PubMed Web of Science ®Google Scholar
• Sosoniuk E, Vallejos G, Kenawy H, et al. Trypanosoma cruzi calreticulin inhibits the complement lectin pathway activation by direct interaction with L-Ficolin. Mol Immunol. 2014 Jul;60(1):80–85.
   PubMed Web of Science ®Google Scholar
• Ferreira V, Valck C, Sanchez G, et al. The classical activation pathway of the human complement system is specifically inhibited by calreticulin from Trypanosoma cruzi. J Immunology. 2004 Mar 1;172(5):3042–3050.
   PubMed Web of Science ®Google Scholar
• Ramirez G, Valck C, Molina MC, et al. Trypanosoma cruzi calreticulin: a novel virulence factor that binds complement C1 on the parasite surface and promotes infectivity. Immunobiology. 2011 Jan-Feb;216(1–2):265–273.
   PubMed Web of Science ®Google Scholar
• Valck C, Ramirez G, Lopez N, et al. Molecular mechanisms involved in the inactivation of the first component of human complement by Trypanosoma cruzi calreticulin. Mol Immunol. 2010 Apr;47(7–8):1516–1521.
   PubMed Web of Science ®Google Scholar
• Gold LI, Rahman M, Blechman KM, et al. Overview of the role for calreticulin in the enhancement of wound healing through multiple biological effects. J Investig Dermatol Symp Proc. 2006 Sep;11(1):57–65.
   PubMedGoogle Scholar
• Goicoechea S, Pallero MA, Eggleton P, et al. The anti-adhesive activity of thrombospondin is mediated by the N-terminal domain of cell surface calreticulin. J Biol Chem. 2002 Oct 4;277(40):37219–37228.
   PubMed Web of Science ®Google Scholar
• McDonnell JM, Jones GE, White TK, et al. Calreticulin binding affinity for glycosylated laminin. J Biol Chem. 1996 Apr 5;271(14):7891–7894.
   PubMed Web of Science ®Google Scholar
• Ito H, Seyama Y, Kubota S. Calreticulin is directly involved in anti-alpha3 integrin antibody-mediated secretion and activation of matrix metalloprotease-2. Biochem Biophys Res Commun. 2001 May 4;283(2):297–302.
   PubMed Web of Science ®Google Scholar
• Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013 Dec 19;369(25):2391–2405.
   PubMed Web of Science ®Google Scholar
• Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013 Dec 19;369(25):2379–2390.
   PubMed Web of Science ®Google Scholar